Despite the introduction of relatively new antineoplastic drugs such as paclitaxel and topotecan in the treatment of advanced ovarian carcinoma, there remains a high percentage of patients who cannot be cured. Intrinsic or acquired resistance to curently available cytotoxic agents is the major obstacle in the treatment of patients with advanced ovarian carcinoma. Increasing the drug dose by e.g. intraperitoneal treatment has a limited additional effect. Therefore, more insight into the cellular mechanisms responsible for both drug response and drug resistance should help to develop more effective treatment methods. In this thesis several studies in ovarian cancer are described, which focus on factors related to drug response and prognosis. Zie: Summary.
To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.